Pharsight

Zydelig patents expiration

ZYDELIG's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
USRE44638 GILEAD SCIENCES INC Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
Aug, 2025

(1 year, 10 months from now)

US8865730 GILEAD SCIENCES INC Polymorphic forms of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one
Mar, 2033

(9 years from now)

US10730879 GILEAD SCIENCES INC Polymorphic forms of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one
Mar, 2033

(9 years from now)

US9469643 GILEAD SCIENCES INC Polymorphic forms of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one
Sep, 2033

(9 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8980901 GILEAD SCIENCES INC 5-fluoro-3-phenyl-2[1-(9H-purin-6-ylamino)propyl]-3H-quinazolin-4-one and 6-fluoro-3-phenyl-2-[1-(9H-purin-6-ylamino)ethyl]-3H-quinazolin-4-one as inhibitors of human phosphatidylinositol 3-kinase delta
May, 2025

(1 year, 7 months from now)

US9149477 GILEAD SCIENCES INC 5-fluoro-3-phenyl-2-[1-(9h-purin-6-ylamino)propyl]-3h-quinazolin-4-one as an inhibitor of human phosphatidylinositol 3-kinase delta
May, 2025

(1 year, 7 months from now)

USRE44599 GILEAD SCIENCES INC Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
Jul, 2025

(1 year, 9 months from now)

US9492449 GILEAD SCIENCES INC Therapies for hematologic malignancies
Mar, 2030

(6 years from now)

Zydelig is owned by Gilead Sciences Inc.

Zydelig contains Idelalisib.

Zydelig has a total of 8 drug patents out of which 0 drug patents have expired.

Zydelig was authorised for market use on 23 July, 2014.

Zydelig is available in tablet;oral dosage forms.

Zydelig can be used as in combination with rituximab, for the treatment of patients with relapsed chronic lymphocytic leukemia (cll), inhibition on pi3k kinase, for the treatment of patients with cll, fl, or sll, for the treatment of patients with cll, fl, or sll; for the treatment of patients with relapsed follicular b-cell non-hodgkin lymphoma or [relapsed] small lymphocytic lymphoma.

The generics of Zydelig are possible to be released after 02 September, 2033.

Drugs and Companies using IDELALISIB ingredient

Market Authorisation Date: 23 July, 2014

Treatment: For the treatment of patients with cll, fl, or sll; Inhibition on pi3k kinase; For the treatment of patients with relapsed follicular b-cell non-hodgkin lymphoma or [relapsed] small lymphocytic lympho...

Dosage: TABLET;ORAL

How can I launch a generic of ZYDELIG before it's drug patent expiration?
More Information on Dosage

ZYDELIG family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic